



For Immediate Release

July 8, 2022

Acuitas Therapeutics to Receive Life Sciences BC Awards

Vancouver, B.C. – Dr. Thomas Madden, President & CEO of Acuitas Therapeutics, is pleased to announce that Acuitas has been recognized as Company of the Year by Life Sciences BC (LSBC). Acuitas Therapeutics' co-founder, Dr. Pieter Cullis, is this year's recipient of LSBC's Global Impact Award.

"We are honoured to have Acuitas Therapeutics named as Company of the Year by Life Sciences BC," said Dr. Madden. "Vancouver's life sciences sector is home to many exceptional organizations and we are proud to be included in this group. We're also excited that our co-founder, Dr. Cullis, has also been recognized by Life Sciences BC with the Global Impact Award."

"A well-deserved congratulations to this year's award winners, who once again showcase the impressive innovation and talent within our province's life sciences community. Not only do their talent and work have a ripple effect on BC's reputation within the larger ecosystem internationally, their contributions directly help move the needle forward for developing life changing treatments, therapies and technologies and most importantly, better access to healthcare for all," said Wendy Hurlburt, President and CEO of Life Sciences BC.

The 2022 Life Sciences BC award winners will be recognized at this year's 24th Annual Life Sciences BC Awards, presented by Farris on September 22, 2022. Learn more about the 24th Annual Life Sciences BC Awards Gala by visiting the LSBC [website](#).

According to the [B.C. Life Sciences Update 2021: Building on a Foundation of Innovation](#) report, British Columbia's ecosystem has never been stronger. The report, released by The Greater Vancouver Board of Trade, in collaboration with LSBC, cites that the province is home to the fastest growing life sciences sector in Canada, employing 18,000+ people at 2,000+ companies. Vancouver also recently ranked the highest of all Canadian cities in the 2021 Life Sciences edition of the [Global Startup Ecosystem Report](#), further demonstrating the critical significance and potential far-reaching impacts of the scientific discoveries and innovations taking place within the province.

A complete list of the 2022 Life Sciences BC award winners is listed on the organization's [website](#).



About Acuitas Therapeutics

Founded in February 2009, Vancouver-based Acuitas Therapeutics (www.acuitastx.com) is a private biotechnology company that specializes in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles. The company partners with pharmaceutical and biotechnology companies, as well as non-governmental organizations and academic institutes to advance nucleic acid therapeutics into clinical trials and to the marketplace. The team works with partners to develop new therapies to address unmet clinical needs based on its internationally recognized capabilities in delivery technology. Acuitas Therapeutics has agreements in place with several partners to use its proprietary lipid nanotechnology in the development of COVID-19 vaccines. This includes Pfizer/BioNTech for COMIRNATY[®], which has received full approval in the U.S. and Canada and is authorized for Emergency Use in Europe, the UK and many other countries.

-END-